Is Mustang Bio going out of business?

MUSTANG BIO, INC. (MBIO) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

MUSTANG BIO, INC. (MBIO) scores 15 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 95.44% (YoY)

Five questions, kept separate

Survival - Fragile

18-26 mo of estimated runway from 2026-06-30, based on $15.2M of cash and short-term investments against $8.2M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

343.7% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 4 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 95.44% (YoY)
• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -12.30%
• Price / Earnings: Unprofitable (see Valuation)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-05.

Price as of 2026-09-07.